BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'
Tweet Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).The analyst comments "Another ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
